UI Hospitals and Clinics
Study for Safety of the Drug Ruxolitnib
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis who have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L
Participants in this study have been diagnosed with Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis or Post Polycythemia Vera Myelofibrosis and have low platelet counts as a consequence of their disease. The study is being done to find out if the drug ruxolitinib is safe and has beneficial effects in people with this disease. There will be approximately 150 subjects across the United States including the University of Iowa.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.